LADENBURG THALM/SH SH Downgrades Coeptis Therapeutics (NASDAQ:COEP) to Hold

Coeptis Therapeutics (NASDAQ:COEP) was downgraded by equities research analysts at LADENBURG THALM/SH SH from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.

Coeptis Therapeutics Stock Performance

COEP stock opened at $0.31 on Tuesday. The stock’s 50 day simple moving average is $0.32 and its 200 day simple moving average is $0.49. Coeptis Therapeutics has a 12-month low of $0.23 and a 12-month high of $1.71. The firm has a market cap of $11.51 million, a P/E ratio of -0.58 and a beta of -0.93. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.03.

Coeptis Therapeutics (NASDAQ:COEP) last issued its earnings results on Friday, May 10th. The company reported ($0.08) earnings per share for the quarter. As a group, equities research analysts predict that Coeptis Therapeutics will post -0.77 EPS for the current year.

Hedge Funds Weigh In On Coeptis Therapeutics

A hedge fund recently raised its stake in Coeptis Therapeutics stock. Armistice Capital LLC increased its stake in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) by 59.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,520,000 shares of the company’s stock after purchasing an additional 1,308,000 shares during the period. Armistice Capital LLC owned 10.32% of Coeptis Therapeutics worth $2,759,000 at the end of the most recent reporting period. 13.88% of the stock is owned by institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.